[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626883":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":39,"centralContacts":43,"locations":27,"responsibleParty":52,"collaborators":27,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":27,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":27,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":79,"whyStopped":27,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":27},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,14,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Scalp nerve blocks plus placebo dexmedetomidine infusion","EXPERIMENTAL","Patients in this group will receive a scalp nerve block with liposomal bupivacaine before surgery. They will receive a continuous intravenous infusion of normal saline (placebo) at the same rate and via identical infusion pumps as used for the dexmedetomidine infusion in the active comparator group.",[13],"Procedure: Scalp-Nerve Block",{"label":15,"type":10,"description":16,"interventionNames":17},"Placebo scalp nerve blocks plus dexmedetomidine infusion","Patients in this group will receive a sham block (no local anesthetic or saline injected). They will receive a continuous intravenous infusion of dexmedetomidine, starting from anesthesia induction until dural closure at a rate of 0.4 μg\u002Fkg\u002Fh, followed by a maintenance dose of 0.05 μg\u002Fkg\u002Fh for 48 hours postoperatively.",[18],"Drug: Dexmedetomidine",{"label":20,"type":10,"description":21,"interventionNames":22},"Both active treatments","Patients in this group will receive scalp nerve block before surgery with liposomal bupivacaine. They will also receive a continuous intravenous infusion of dexmedetomidine intravenously at a rate of 0.4 μg\u002Fkg\u002Fh from anesthesia induction until dural closure, followed by a maintenance dose of 0.05 μg\u002Fkg\u002Fh for 48 hours postoperatively.",[18,13],{"label":24,"type":25,"description":26,"interventionNames":27},"Double placebo","NO_INTERVENTION","Patients in this group will receive a sham scalp nerve block (no injection). The patients in this group will not receive scalp nerve block. From the start of surgery until 48 hours postoperatively, they will receive a continuous intravenous infusion of normal saline (placebo) at the same rate and via identical infusion pumps as used for the dexmedetomidine infusion in the active comparator group.",null,[29,34],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":27},"DRUG","Dexmedetomidine","The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug\u002Fkg\u002Fh intraoperatively and 0.05 μg\u002Fkg\u002Fh for 48 hours after surgery.",[20,15],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":27},"PROCEDURE","Scalp-Nerve Block","The 10ml 1.33% liposomal bupivacaine will be diluted into a 20ml syringe. As for scalp nerve block, each nerve will be blocked separately with 1-2 mL 0.67% liposomal bupivacaine.",[20,9],[40],{"name":41,"affiliation":5,"role":42},"Yuming Peng, Dr","PRINCIPAL_INVESTIGATOR",[44,49],{"name":45,"role":46,"phone":47,"phoneExt":27,"email":48},"Min Zeng, Dr","CONTACT","8610-59976658","fly800727@163.com",{"name":50,"role":46,"phone":47,"phoneExt":27,"email":51},"Muhan Li, Dr","limuhan8816@163.com",{"type":42,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"Yuming Peng","Deputy chief of Department of Anesthesiology","100626883","perioperative-multimodal-analgesia-for-supratentorial-craniotomy-100626883",false,"NCT07441421","Perioperative Multimodal Analgesia for Supratentorial Craniotomy","Perioperative Multimodal Analgesia for Supratentorial Craniotomy：Protocol for a 2× 2 Factorial Randomized Trial","Inclusion Criteria:\n\n* Aged from 18 to 65 years\n* American Society of Anesthesiologists physical status I to III\n* Scheduled to undergo elective supratentorial tumor resection\n\nExclusion Criteria:\n\n* Incision-area skin infection\n* A history of previous craniotomy\n* Allergy to study medications\n* A history of preoperative change in consciousness or cognitive function\n* Inability to communicate,\n* Preoperative pain in the surgical region\n* Severe hepatic or renal dysfunction\n* Severe bradycardia (heart rate\\\u003C40 beats\u002Fmin)\n* Sick sinus syndrome or second- to-third degree atrioventricular block","ALL","18 Years","65 Years",{"count":66,"type":67},2000,"ESTIMATED","INTERVENTIONAL",[70],"NA","This randomized clinical trial aims to evaluate the effectiveness of scalp nerve blocks and dexmedetomidine in reducing opioid use and preventing postoperative delirium in patients undergoing supratentorial brain tumor surgery. A total of 2000 patients will be randomly assigned to one of four groups, receiving either active treatments, placebos, or their combinations. The main outcome measured will be the amount of opioid pain medication needed after surgery.",[73,74,75],"Postoperative Pain","Analgesia","Supratentorial Brain Tumor",[77,78],"multimodal analgesia","postoperative acute pain","NOT_YET_RECRUITING","2026-02-25",{"date":82,"type":83},"2026-03-02","ACTUAL",{"date":85,"type":67},"2026-03-01",{"date":87,"type":67},"2027-12-31",{"name":5,"class":6}]